Zymeworks develops antibody medicines for cancer and immune diseases and partners with drugmakers to sell them. ZYME reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 28 | Truist Securities | Target raised | Buy | |
| Oct 7 | Truist Securities | Target raised | Buy | |
| Sep 29 | Citigroup | Target raised | Buy | |
| Sep 3 | JP Morgan | Maintained | Buy | |
| Aug 26 | Citigroup | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in ZYME in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ZYME is in one of them and how their past ZYME trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ZYME in an article yet. Here's the latest on the wider market.
About Zymeworks
Zymeworks is a biotechnology company based in Middletown, Delaware. It develops medicines built from antibodies for cancer, inflammation and autoimmune disease, using its own technology platforms. Its partners are drugmakers that share development costs and sell the treatments, and Zymeworks earns milestone payments and royalties from those partnerships.
- Headquarters
- Middletown, DE
- Founded
- 2003
- Website
- zymeworks.com ↗